MedTrace Logo

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

NCT00545610 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-11-28

No results posted yet for this study

Summary

The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+ cells on quality of life (QoL) in subjects with chronic refractory myocardial ischemia. No treatments will be administered during this study. However, the investigators and other study site personnel and the subjects will remain blinded to the treatment assignments from the core therapeutic study (# 24779) so as to provide a total of 24 months of blinded data.

Conditions

  • Myocardial Ischemia

Sponsors & Collaborators

  • Lisata Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Caladrius Study Director · Lisata Therapeutics, Inc.

Eligibility

Min Age
21 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-04-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545610 on ClinicalTrials.gov